WO2000023476A1 - Peptides specifiques pour la neovascularisation - Google Patents
Peptides specifiques pour la neovascularisation Download PDFInfo
- Publication number
- WO2000023476A1 WO2000023476A1 PCT/JP1999/005730 JP9905730W WO0023476A1 WO 2000023476 A1 WO2000023476 A1 WO 2000023476A1 JP 9905730 W JP9905730 W JP 9905730W WO 0023476 A1 WO0023476 A1 WO 0023476A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- seq
- cancer
- amino acid
- neovascular
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 400
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 81
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 146
- 201000011510 cancer Diseases 0.000 claims abstract description 104
- 239000000412 dendrimer Substances 0.000 claims abstract description 66
- 229920000736 dendritic polymer Polymers 0.000 claims abstract description 66
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 10
- 150000001413 amino acids Chemical class 0.000 claims description 95
- 238000000034 method Methods 0.000 claims description 95
- 210000004204 blood vessel Anatomy 0.000 claims description 64
- 230000002401 inhibitory effect Effects 0.000 claims description 36
- 239000002246 antineoplastic agent Substances 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 33
- 239000004480 active ingredient Substances 0.000 claims description 23
- 230000001093 anti-cancer Effects 0.000 claims description 18
- 206010027476 Metastases Diseases 0.000 claims description 14
- 230000009401 metastasis Effects 0.000 claims description 13
- 206010039491 Sarcoma Diseases 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 6
- 239000002257 antimetastatic agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 31
- 229940079593 drug Drugs 0.000 abstract description 28
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 230000006872 improvement Effects 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 61
- 239000002502 liposome Substances 0.000 description 55
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 52
- 239000000243 solution Substances 0.000 description 37
- 230000004614 tumor growth Effects 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 31
- 230000000694 effects Effects 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 27
- 239000000126 substance Substances 0.000 description 27
- 229940009456 adriamycin Drugs 0.000 description 25
- 230000000259 anti-tumor effect Effects 0.000 description 24
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 239000006185 dispersion Substances 0.000 description 24
- 230000036961 partial effect Effects 0.000 description 24
- 210000000056 organ Anatomy 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 206010029113 Neovascularisation Diseases 0.000 description 20
- 230000033115 angiogenesis Effects 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 239000012153 distilled water Substances 0.000 description 16
- 239000011347 resin Substances 0.000 description 16
- 229920005989 resin Polymers 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 15
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 13
- 150000003904 phospholipids Chemical class 0.000 description 13
- 238000002054 transplantation Methods 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 210000003462 vein Anatomy 0.000 description 12
- -1 4- (Hydroxymethyl) phenoxy group Chemical group 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 210000003705 ribosome Anatomy 0.000 description 11
- 238000010532 solid phase synthesis reaction Methods 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 230000008685 targeting Effects 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 230000001332 colony forming effect Effects 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 150000003905 phosphatidylinositols Chemical class 0.000 description 9
- 230000002378 acidificating effect Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 238000012377 drug delivery Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 238000010647 peptide synthesis reaction Methods 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 210000002969 egg yolk Anatomy 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical group N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- 239000000032 diagnostic agent Substances 0.000 description 5
- 229940039227 diagnostic agent Drugs 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 5
- 229940067626 phosphatidylinositols Drugs 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000006957 competitive inhibition Effects 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 235000013345 egg yolk Nutrition 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 230000036326 tumor accumulation Effects 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- VIWQOOBRKCGSDK-RYQLBKOJSA-N Trp-Arg-Pro Chemical group C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)O VIWQOOBRKCGSDK-RYQLBKOJSA-N 0.000 description 3
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 239000012830 cancer therapeutic Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 239000002960 lipid emulsion Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 description 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 2
- ZLGYVWRJIZPQMM-HHHXNRCGSA-N 2-azaniumylethyl [(2r)-2,3-di(dodecanoyloxy)propyl] phosphate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCC ZLGYVWRJIZPQMM-HHHXNRCGSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- FQZQXPXKJFOAGE-KICCZPNWSA-N [(2r)-3-[hydroxy-[(5r)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)OC1C(O)C(O)C(O)[C@@H](O)C1O FQZQXPXKJFOAGE-KICCZPNWSA-N 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LHCZDUCPSRJDJT-UHFFFAOYSA-N dilauroyl phosphatidylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCC LHCZDUCPSRJDJT-UHFFFAOYSA-N 0.000 description 2
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 2
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 2
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229940105631 nembutal Drugs 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 125000001095 phosphatidyl group Chemical group 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- YDIKCZBMBPOGFT-DIONPBRTSA-N (2s,3r,4s,5s,6r)-2-[5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)chromenylium-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride Chemical compound [Cl-].COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 YDIKCZBMBPOGFT-DIONPBRTSA-N 0.000 description 1
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IBUKXRINTKQBRQ-KCKFLZCVSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-D-myo-inositol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O IBUKXRINTKQBRQ-KCKFLZCVSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- XQISPVJWRLHHLT-UHFFFAOYSA-N 1-hydroxycyclohexa-2,4-diene-1-carboxylic acid Chemical compound OC(=O)C1(O)CC=CC=C1 XQISPVJWRLHHLT-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- TXLHNFOLHRXMAU-UHFFFAOYSA-N 2-(4-benzylphenoxy)-n,n-diethylethanamine;hydron;chloride Chemical compound Cl.C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 TXLHNFOLHRXMAU-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ATAFDSCDEDHMOK-UHFFFAOYSA-N 3,3-diaminopropanoic acid Chemical compound NC(N)CC(O)=O ATAFDSCDEDHMOK-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-O 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-O 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 101100129088 Caenorhabditis elegans lys-2 gene Proteins 0.000 description 1
- 101100459439 Caenorhabditis elegans nac-2 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 description 1
- 101710087078 Dipeptidyl peptidase 1 Proteins 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 101150118523 LYS4 gene Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100025818 Major prion protein Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 101100521383 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) prp-5 gene Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000232219 Platanista Species 0.000 description 1
- 229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- MMIMIFULGMZVPO-UHFFFAOYSA-N benzyl 3-bromo-2,6-dinitro-5-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=C(C(=O)OCC=2C=CC=CC=2)C([N+](=O)[O-])=C(Br)C=C1OCC1=CC=CC=C1 MMIMIFULGMZVPO-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004169 mitoxantrone hydrochloride Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920006289 polycarbonate film Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229960001586 procarbazine hydrochloride Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000008348 synthetic phosphatidyl choline Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 235000019583 umami taste Nutrition 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960005212 vindesine sulfate Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Neovascular specific peptides
- the present invention functions as a ligand for neovascular endothelial cells of cancer tissue, more specifically, a peptide molecule that selectively returns to neovascularization, and is useful as a molecular drug.
- a new blood vessel-specific peptide that can be applied to drug delivery system (DDS) preparations that can selectively deliver drugs to target tissues and can contribute to the improvement of cancer treatment effects .
- DDS drug delivery system
- DDS Drug Delivery System
- DDS targeting cancer can be broadly classified into two types: passive targeting and active targeting. Because new blood vessels have enhanced vascular permeability compared to existing blood vessels, long-term retentive preparations gradually accumulate in cancer tissues. Tar utilizing its properties Targeting is passive targeting, and in Europe and the United States, passive pig-targeting preparations using ribosomes have already been used for the treatment of lipopositive sarcoma.
- active preparations modify drugs with antibodies or other ligands that bind to cell surface markers such as proteins highly expressed in cancer cells and surrounding tissues, and are harmful to normal tissues. It is a drug designed to deliver a drug positively and selectively to cancer tissue without any significant effect.
- angiogenesis In the field of cancer treatment, angiogenesis is drawing attention.
- This angiogenesis refers to the development of blood vessels inside the cancer tissue at the same time as the cancer grows.
- blood vessels which are organs that supply nutrients, supply oxygen, and excrete metabolic waste, are newly constructed.
- angiogenesis it can be said that the growth of cancerous tissues depends heavily on angiogenesis.
- DDS formulations DDS formulations
- An object of the present invention is to provide such a new ligand.
- Another object of the present invention is to provide a substance that suppresses angiogenesis.
- the present inventors have obtained the following findings in the course of intensive research from the above purpose. That is, first, the present inventors used a Jiangno, one-ring method (Folkman, J., et al., J. Exp. Med., Ill, 275-288 (1971)) to produce a tumor on the back of a mouse. After induction of neovascularization, random DNA is inserted into the phage coat protein P111 gene and a random 15 amino acid sequence peptide is inserted into the phage outer surface. A random peptide display phage constructed so as to be able to express E.
- a Jiangno one-ring method
- coli is administered to the mouse, and then the mouse is frozen with liquid nitrogen, the skin on which new blood vessels are formed is cut off, and a protease inhibitor is contained. After homogenizing in a culture solution, washing and centrifuging, the phage is collected from the new blood vessel, infected with Escherichia coli, cultured in large amounts, separated, purified, and accumulated on the neovascular endothelium. A peptide expression phage was obtained. With respect to the plurality of phages thus obtained, the peptides expressing them were sequenced.
- each of the phages obtained above was administered into the tail vein of a cancer-bearing mouse transplanted with cancer cells.
- mice were frozen with liquid nitrogen, cancer tissues were excised and excised, phages were separated and purified from the obtained material, infected with Escherichia coli, and cultured.
- the colony forming units of the phage were measured using the phage before selection as a control, and the affinity for new blood vessels was measured in the tail vein per 100 mg of cancer tissue.
- the ratio was calculated as the ratio of the number of accumulated phages to the number of administered phages, thus obtaining candidate peptides as ligands with high affinity for neovascularization.
- the present inventors have synthesized the above-mentioned peptide, dendrimer of the above-mentioned peptide, partial peptide of the above-mentioned peptide, and the like, and these have an actual antitumor effect. And that the intratumoral distribution of liposomes modified with the above peptides, especially those containing the Trp_Arg-Pro sequence and the Pro-Arg-Pro sequence, is significantly higher than that of the control. It was confirmed.
- the present invention has been completed based on these findings.
- a neovascular-specific peptide which selectively returns to a new blood vessel and is one of the following (a) and (b): Is provided.
- a peptide having any of the amino acid sequences shown in SEQ ID NOs: 1 to 11 or the above-mentioned neovascular-specific peptide which is a dendrimer thereof More preferably, a peptide having any of the amino acid sequences shown in SEQ ID NOs: 1, 5 and 6, or the above-mentioned neovascular-specific peptide which is a dendrimer thereof; SEQ ID NOS: 1 to 11 A neovascular-specific peptide which is a dendrimer containing a plurality of identical or different peptides of the amino acid sequence represented by the amino acid sequence; the amino acid sequence represented by SEQ ID NOS: 12 to 17 A peptide having any one of the above or a dendrimer thereof; and the above-mentioned peptide specific to neovascularization; and an amino acid represented by SEQ ID NOS: 19, 21, 23 to 25 and 28 to 32 A peptide having any of the
- neovascular-specific peptide which is a peptide that selectively returns to a neovascular vessel formed in a cancer tissue, for example, a sarcoma or a melanoma.
- At least one of the above-mentioned neovascular-specific peptides preferably, SEQ ID NOs: 1, 5, 6, 13 to; 17, 19, 21, 2,
- a peptide having any of the amino acid sequences represented by 3 to 25 and 28 to 32 or at least one of its dendrimers is used as an active ingredient, and is formulated into a pharmaceutical preparation.
- An anticancer composition and a composition for suppressing cancer metastasis contained together with a carrier are provided.
- the present invention provides a liposome preparation comprising, as an active ingredient, a drug or at least one of its dendrimers, and an anticancer agent or a cancer metastasis inhibitor, together with a drug carrier.
- an anticancer and cancer metastasis suppressing method comprising administering to a patient an effective amount of at least one kind of the above-mentioned neovascular-specific peptides, in particular, SEQ ID NOS: 1, 5, 6, 13 to At least one peptide having any of the amino acid sequences represented by 17, 19, 21, 21, 23 to 25 and 28 to 32 or a dendrimer thereof; System to administer an effective amount to patients A method for inhibiting cancer and cancer metastasis is provided.
- the ribosome preparation preferably a peptide having any of the amino acid sequences shown in SEQ ID NOS: 15 to 17 or a small amount of its dendrimers.
- the present invention provides a method for inhibiting cancer and metastasis, which comprises administering to a patient a liposome preparation containing at least one kind as an active ingredient and an anticancer agent or a cancer metastasis inhibitor together with a preparation carrier.
- new blood vessel-specific peptide of the present invention include those having the amino acid sequence shown in SEQ ID NOS: 1 to 11 obtained by the method described in Examples described later. it can.
- a molecular library screening method can be adopted.
- the fuzzy display library is preferable. Can be illustrated. One such library is ⁇ You can use those sold.
- the random peptide display phage in the library uses specific target molecules or cells of interest to identify peptides that specifically bind to the target molecules or cells. It is used to express multiple peptides that can be screened at the mouth. Screening using the library is used to identify ligands that specifically bind to various cell surface receptors, and various antibodies.
- a method more preferably used for identifying a neovascular-specific peptide as a molecule capable of returning to a neovascularization of the present invention for example, Japanese Patent Application Laid-Open No. H10-502102
- An example is a method for identifying a molecule returning to an organ or tissue of Luos Rati et al. Described in Publication No. 674 (corresponding US Pat. No. 5,622,699).
- the method uses one, two or three selected organs by using in vivo vanning to screen a library of potential organ homing molecules.
- a method for identifying a molecule that specifically returns to a tissue can be performed as follows.
- phage-infected E random DNA is introduced into a known phage library, and a diluted mixture of the obtained phage library is administered to, for example, the tail vein of a mouse. Quick freeze in nitrogen.
- the cadaver is thawed, the desired organ or tissue is collected, homogenized in a culture solution containing a protease inhibitor, and the obtained sample is subjected to 1% serum serum. After washing several times with an ice-cold culture medium containing albumin, infect Escherichia coli. The phage-infected E.
- coli is cultured for several hours in a medium containing tetracycline, and then pre-coated on an agar plate containing tetracycline, and the recovered phage is collected.
- the containing colony is further cultured in a suitable medium to separate and purify the phage.
- the second and subsequent biopannings are performed.
- the second and subsequent in-vivo panning can be performed in the same manner as described above using the phage obtained above.
- one can obtain DNA encoding the peptide expressed by the desired selected phage.
- sequencing the resulting DNA molecules that return to the desired organ or tissue can be identified.
- Sequencing of the DNA is performed by methods known in the art. For example, the dideoxy method [Proc. Nat 1. Acad. Sci., USA., 74, 5463-5467 (1977)] or the maxam-Gilnot method [Method in Enzymology, 61, 99 (1980) )] Etc. Such a nucleotide sequence can be easily determined using a commercially available sequence kit or the like.
- the following method can be adopted. That is, in the method for identifying a molecule that specifically returns to an organ or tissue, the obtained phage expressing the organ or tissue-specific peptide and the phage before selection are administered into the tail vein of the experimental animal.
- the colony forming units of the phage are measured in the same manner as described above, and for example, the number of accumulated phages relative to the number of phages administered into the tail vein per 10 O mg of the target organ or tissue.
- the affinity of molecules returning to the desired organ or tissue can be detected.
- one of the target organ or tissue return peptides is selected by, for example, a competitive method, and the peptide is synthesized and purified by high performance liquid chromatography (HPLC).
- HPLC high performance liquid chromatography
- neovascular-specific peptides of the present invention identified by using in vivo panning in mice described in the Examples below can bind to neovascular tissue of cancer in humans or other mammalian species.
- the peptides of the present invention that bind to a target molecule present in neovascularization grown in mice can bind to the corresponding target molecule in neovascularization of cancer in humans or other mammals.
- the peptides of the present invention can specifically bind to a sample obtained from a patient in vitro.
- the formation of blood vessels in cancerous tissue is characterized by the occurrence of a continuous formation of new blood vessels that support growth, and is distinguished from general histological blood vessel formation in this respect (Folkman , Nat. Med., ⁇ , 27-31 (1995); Rak, Anticancer Drugs, 6, 3-18 (1995)). Therefore, the same
- the peptide of the present invention which specifically returns to defined neovascularization can be used as a suppressor of neovascularization against cancer.
- the peptide of the present invention which specifically returns to a new blood vessel, is unlikely to have an adverse effect on normal and healthy organs or tissues.
- the peptide of the present invention returns to a new blood vessel instead of a cancer cell, it is considered that there is a low possibility of acquiring drug resistance such as an anticancer drug.
- the peptides of the present invention that specifically return to neovascularization may be used to target other types of neovascular systems such as those present in inflammatory, regenerating or injured tissues.
- the peptide of the present invention is considered to also have a binding property to such uterine tissues, and can be expected to have an effect on diseases such as uterine fibroids. .
- the peptides of the present invention identified and confirmed as described above are specified by SEQ ID NOS: 1 to 11, and all have the property of returning to neovascularization. It is characterized.
- the peptide of the present invention includes, in addition to the peptide having the amino acid sequence represented by SEQ ID NOS: 1 to 11, one or more amino acids in the amino acid sequence. Is replaced, missing Peptides having an amino acid sequence modified by loss or addition and having affinity for new blood vessels, that is, peptides having the property of returning to new blood vessels, are included.
- the degree of “substitution, deletion or addition” of amino acids and their positions are determined by the amino acids represented by SEQ ID NOs: 1 to 11
- the above-mentioned modification (mutation) of the amino acid sequence may occur naturally, for example, due to mutation or post-translational modification, but is artificially modified based on a naturally-occurring gene. You can.
- the present invention encompasses all modified peptides having the above-mentioned properties, irrespective of the cause and means of such modification / mutation.
- the peptides of the present invention also include homologs of the peptides having the amino acid sequence represented by SEQ ID NOS: 1 to 11.
- Such homologues include mammalian proteins having the same activity as the amino acid sequence of the amino acid sequence represented by SEQ ID NOS: 1 to 11, such as human, poma, hidge, pishi, dog, and the like. It also includes proteins from rodents such as sal, cats, bears, rats, and rabbits.
- Examples of the peptide of the present invention having the above modified amino acid sequence include, for example, SEQ ID NOs: 1, 5, and 6. Sequences that are partially overlapping in the sequence
- Specific examples of the peptide of the present invention in which a part of the above amino acid sequence is modified include, for example, those comprising 12 amino acid residues shown in SEQ ID NO: 19; SEQ ID NO: 12 Those comprising 8 amino acid residues shown in SEQ ID NOs: 14 to 21; those comprising 5 amino acid residues shown in SEQ ID NOS: 15 to 17 and 23 to 25; SEQ ID NO: 2 Those consisting of 4 amino acid residues shown in 8 to 31; and those consisting of 3 amino acid residues (Trp-Arg-Pro) shown in SEQ ID NO: 32, and the like. More specifically, for example, in the case of SEQ ID NO: 12, only the amino acid sequence of the 4th to 11th amino acids in SEQ ID NO: 11 is left.
- sequence shown in SEQ ID NO: 13 of the 15 amino acid sequences shown in SEQ ID NO: 5, 8 amino acid sequences are left from the N-terminal, and the remaining 7 amino acid residues are removed. It has been deleted.
- the sequence shown in SEQ ID NO: 14 consists of an 8 amino acid sequence obtained by deleting 7 amino acid residues from the N-terminal of the amino acid sequence shown in SEQ ID NO: 6.
- the sequence shown in SEQ ID NO: 15 consists of 2 to 6 amino acid sequences of the amino acid sequence shown in SEQ ID NO: 5.
- the sequence shown in SEQ ID NO: 16 consists of the 9 to 13 amino acid sequence of SEQ ID NO: 6.
- the amino acid sequence shown in SEQ ID NO: 17 is obtained by adding A1a to the N-terminus of the amino acid sequence of 1-4 amino acids in the amino acid sequence shown in SEQ ID NO: 1.
- a peptide having at least two cystine residues for example, a peptide having an amino acid sequence represented by SEQ ID NO: 11 is considered to be spontaneously circularized. Since such a cyclic peptide may have activity even when present in a linear form, one or both cysteine residues in the peptide may be used in the present invention. It can be deleted without significantly affecting the homing properties of the peptide. Such a phenomenon is supported, for example, in the report of Koivunen et al. (Koivunen, et al., J. Biol. Chem., 268, 20205-20210 (1993)). A specific example of the peptide having the amino acid sequence deleted above is as shown in SEQ ID NO: 12. Such a peptide having a partially deleted amino acid sequence is also a feature of the neovascular homing characteristic described above. O 0 476
- neovascular-specific peptide to “the peptide of the present invention” are partially based on the amino acid sequence of SEQ ID NOS: 1 to 11 described above.
- Peptides having a modified amino acid sequence such as partial peptides in which the amino acid sequence has been deleted, are also included.
- novel blood vessel-specific peptide according to the present invention also includes a peptide having an amino acid sequence represented by any one of SEQ ID NOS: 1 to 11; In addition to peptides that have the property of returning to, the dendrimers of these peptides are included.
- dendrimer is known as a macromolecule of spherical or other three-dimensional structure having a certain composition and molecular weight, and is also known as a multi-antigen peptide. Also known as peptide: MAP).
- a branch having the same functional group as the chemical structural nucleus in each functional group at its end (repeat unit) ) are combined, and the same repeating unit is successively introduced into the terminal functional group.
- the dendrimer is a nuclear structure that is a starting portion having a spherical appearance having a star configuration from its dendritic shape, and a repeating unit radially bonded to the starting nucleus. It has an inner surface (generation) that is composed and an outer surface consisting of activated functional groups bonded to the outermost end of each branch.
- the size, morphology and reactivity of dendrimers are determined by the choice of the starting nucleus, the number of generations determined in producing the dendrimers, and the repeating units used for each generation. Can be adjusted.
- Dendrimers of different sizes can easily be obtained by increasing the number of generations used, and their manufacture is described, for example, in US Pat. No. 4,694,644. You can refer to the description in the book.
- the nitrogen atom is used as the starting portion of the core structure, and is bonded to the core structure portion.
- the functional groups include dendrimers comprising the angiogenesis-specific peptide of the present invention consisting of SEQ ID NOs: 1 to 17, or lysine, which is described in Examples below.
- Amino acids such as arginine, glutamic acid, and aspartic acid are used as a core structural part, and a repeating unit that is directly bonded to the core structural part is also used as the amino acid, and an activated functional group is also used.
- the amino acid sequence of the present invention selected from SEQ ID NOS: 1 to 17 or the peptide selected from SEQ ID NOs: 19, 21, 23 to 25 and 28 to 32
- the dendrimer having the angiogenesis-specific peptide of the present invention having the amino acid sequence of the present invention can be exemplified.
- the dendrimer having a nitrogen atom as a starting part is commercially available from, for example, Polysciences, Inc., 400 Vally Road, Warrington, PA, 18976, USA. Using the solid phase synthesis method described later, it is possible to produce a dendrimer in which the angiogenesis-specific peptide of the present invention is bound to the outermost end of each branch. Similarly, a lysine is used as a starting core structure, and a repeating unit consisting of lysine is also used for the amino acid that binds directly to the nucleus, and a solid-phase synthesis method described later. Can be used to produce a dendrimer in which the angiogenesis-specific peptide of the present invention is bound to the outermost end of each branch. This dendrimer has Watanabe 2376
- Each of the above dendrimers can be synthesized, for example, as follows. That is, the solid-phase peptide resin for synthetic, space - alpha were protected 2 Tsunoa Mi amino group not through or via a server with a protecting group is not a same or identical, omega - di ⁇ Mi Amino Acids Is a repeating unit, and by repeating the condensation of the repeating unit and the removal of the protecting group, a dendrimer can be obtained.
- resins for solid phase peptide synthesis include a methyl group at the end of polystyrene resin, polyacrylamide resin, polystyrenepolyethylene glycol resin, and the like.
- Resins used for peptide synthesis can be used.
- One or more amino acids are listed as spacers. I can do it.
- Examples of the ⁇ , ⁇ -diaminic acid include lysine, orditin, 1,4-diaminoenic acid, and 1,3-diaminopropionic acid.
- Examples of the protecting group include a Boc group, an Fmoc group, and a Z group. Therefore, examples of the functional group include an amino group, a carboxyl group, and a hydroxyl group.
- the number of branches is 2 n by repeating the condensation of the repeating unit and removing the protecting group n times. Specifically, the number is 2 to 16.
- Dendrimers Purification of such dendrimers is accomplished using conventional techniques, for example, chromatography on resins such as Sephacryl S-300 (Pharmacia) using a matrix-removable resin. This can be done by one operation such as graphing.
- resins such as Sephacryl S-300 (Pharmacia) using a matrix-removable resin. This can be done by one operation such as graphing.
- the dendrimer peptide thus obtained is characterized in that the angiogenesis-specific peptide of the present invention present in the branch portion selectively returns to the original angiogenesis and suppresses angiogenesis. It exerts an effect, and thus can exert a desired anti-cancer effect and an effect of suppressing cancer metastasis.
- the dendrimer peptide when the dendrimer peptide is packaged and administered with a known drug having an anticancer effect, the dendrimer peptide can act on the target angiogenesis portion only, and further has side effects. It has the advantage that it can be used as a drug with less amount.
- the angiogenesis-specific peptide of the present invention to be present does not need to be the same peptide in each branch, and may be a combination of a plurality of peptides having different amino acid sequences. Examples thereof include the amino acid sequence peptides of SEQ ID NO: 1, SEQ ID NO: 5, and SEQ ID NO: 6, or the 15 amino acid sequence peptides of SEQ ID NOs: 1 to 11.
- Such a dendrimer can improve the stability in blood and tissue, the specific activity of the bound molecule, and the like in the administration subject.
- the new blood vessel-specific peptide of the present invention can be produced by a general chemical synthesis method according to its amino acid sequence.
- the method includes a peptide synthesis method by a usual liquid phase method and a solid phase method. More specifically, such peptide synthesis methods include a stepwise method in which amino acids are sequentially linked one by one to extend the chain based on amino acid sequence information, and A fragment consisting of several amino acids is synthesized in advance, and then each fragment is cut. And a fragment condensation method in which a printing reaction is performed.
- the synthesis of the novel blood vessel-specific peptide of the present invention can be based on any of them.
- the condensation method employed in the peptide synthesis can also be in accordance with various known methods. Specific examples include the azide method, the mixed acid anhydride method, the DCC method, the active ester method, the oxidation-reduction method, the DPPA (diphenylphosphoryl azide) method, and the DCC + additive (1-hydroxybenzoic acid method). Examples include triazole, N-hydroxysuccinamide, N-hydroxy-5-norporenene 2,3-dicaroxyimidide), and the Wooddid method.
- the solvent that can be used in each of these methods can be appropriately selected from general solvents that are well known to be used in this kind of peptide condensation reaction.
- NMP N-methylpyrrolidone
- DMF dimethylformamide
- DMSII dimethylsulfoxide
- THF tetrahydrofuran Lanthanum
- ethyl acetate examples include N-methylpyrrolidone (NMP), dimethylformamide (DMF), dimethylsulfoxide (DMSII), hexaphosphoroamide, dioxane, tetrahydrofuran Lanthanum (THF), ethyl acetate and the like and a mixed solvent thereof can be mentioned.
- the carboxyl group in the amino acid and the peptide not involved in the reaction is generally esterified to form, for example, methyl ester, ethyl ester, tertiary butyl ester.
- Lower alkyle Can be protected as steles, for example, benzyl ester, p-methoxybenzyl ester, p-dibenzyl ester aralkyl ester.
- Amino acids having a functional group in the side chain may be protected with an acetyl group, a benzyl group, a benzyloxycarponyl group, a tertiary butyl group, etc. There is no need to provide such protection.
- the guanidino group of Arg includes nitro group, tosyl group, 2—methoxybenzenesulfonyl group, methylene-12-sulfonyl group, benzyloxycarbonyl group, and isobornyloxycarbonyl group. Or an appropriate protecting group such as an adamantyl oxycarbonyl group.
- the deprotection reaction of these protecting groups in the amino acid having the above-mentioned protecting group, the peptide and the finally obtained new blood vessel specific peptide of the present invention can also be performed by a commonly used method, for example, a catalytic reduction method, It can be carried out according to a method using liquid ammonia sodium, hydrogen fluoride, hydrogen bromide, hydrogen chloride, trifluoroacetic acid, acetic acid, formic acid, methanesulfonic acid and the like.
- neovascular-specific polypeptide of the present invention can be produced by a conventional method, for example, ion-exchange resin, distribution chromatography, gel chromatography, gel chromatography.
- Initiative chromatograph, high-performance liquid chromatograph Purification can be performed as appropriate according to a method widely used in the field of peptide chemistry, such as feed (HPLC) and countercurrent distribution.
- novel blood vessel-specific peptide of the present invention (including its dendrimer, hereinafter the same) obtained as described above has an effect of specifically returning to a new blood vessel, and is capable of forming a new blood vessel by itself. It is useful as an angiogenesis inhibitor.
- the neovascular-specific peptide of the present invention since it has an action of specifically returning to neovascularization of cancer tissue, it is used as a ligand for cancer tissue, for example, an anticancer agent such as a cancer chemotherapeutic agent. It can be used in combination with other drugs.
- the target various cancer diseases include, for example, melanoma, colorectal cancer, ovarian cancer, liver cancer, breast cancer, brain tumor, kidney cancer, Teng kidney cancer, cervical cancer, esophageal cancer, lung cancer, gastric cancer And the like.
- 5—fluorouracil 5—FU
- 5—FU fluorouracil
- Alkylating agents such as cyclophosphamide, melphalan, ranimustine, diphosphamide, nitrodiene master hydrochloride N—salt, etc .
- antimetabolites such as 6 _ Mercaptopurin, liposide, enoside Bin, carmofur, shilababin, shirababinokhoshu ehort, tegafur, 5 — FU, doxyfluridine, doxyfluridine, hydroxycarbamide, fluorouracil, methotrexate, mercapto Toprin, etc .
- antitumor antibiotics such as actinomycin D, aclarubicin hydrochloride, idarubicin hydrochloride, epilubicin hydrochloride, doxorubicin hydrochloride, daunorubicin hydrochloride, pyrarubicin hydrochloride, bleomycin hydrochloride, dinosutin stima Lamar,
- I FN_o As a site force anti-tumor activity, I FN_o ;, IFN-3, IFN- ⁇ , IL-1, IL-2, IL-12, TNF, TGF- / 3, Angiostin, Troponspondin, Endosustin, etc. Is done.
- the antibody or antibody fragment include an antibody against a factor associated with cancer growth and promotion, such as an anti-VEGF antibody, an anti-FGF antibody, an anti-HGF antibody I and an anti-L-8 antibody, or an antibody fragment thereof.
- novel blood vessel-specific peptide of the present invention can be used to bind or modify an active drug such as an anticancer agent or a cytokine having anticancer activity into a liposome preparation such as DDS.
- a formulation can be made and such a formulation can be active for cancer.
- the new blood vessel-specific peptide of the present invention is bound to a protein having anticancer activity, such as a cytodynamic protein
- a conjugate can be obtained by combining the peptide of the present invention with the above-described cytochrome according to a genetic recombination technique. It can be expressed as a fusion protein with protein or the like.
- the production and expression of such a fusion protein can be performed according to conventional techniques well known in the art. That is, the fusion protein can be prepared by a conventional gene recombination technique (for example, Science, 224, 1431 (1984); Biochem. Biophys. Res. Comm., 130, 692 (1985); Proc. Natl. Acad. Sc.
- the obtained recombinant fusion protein can be subjected to various separation operations utilizing its physical properties, chemical properties, etc. [“Biochemical Data Book II”, pp. 1175-1259, 1st edition, 1st edition, if desired. Printing, June 1980 Published by Tokyo Chemical Dojin Co., Ltd .;
- Examples of the method include, for example, ordinary reconstitution treatment, treatment with a protein precipitant (salting out method), centrifugal separation, osmotic shock method, ultrasonic crushing, ultrafiltration, molecular sieve screening Chromatography (gel filtration), adsorption chromatography, ion-exchange chromatography, affinity chromatography, high-performance liquid chromatography
- Examples include various liquid chromatographies such as (HPLC), dialysis methods, and combinations thereof. Particularly preferred examples of the above method include affinity chromatography using a column to which a desired protein is bound.
- novel blood vessel-specific peptide of the present invention is combined with a physical, chemical or biological substance to form a ligand.
- the physical, chemical or biological substance is a drug delivery system substance, such as a microdevice with a chamber that can contain the cancer chemotherapeutic agent (anticancer agent, etc.).
- a drug delivery system substance such as a microdevice with a chamber that can contain the cancer chemotherapeutic agent (anticancer agent, etc.).
- Examples of such drug delivery systems include biology such as liposomes, microporous capsules containing permeable or semi-permeable membranes, and microdevices with other chambers. Substances can be mentioned. These should generally be non-toxic and, preferably, biodegradable.
- the liposome preparation is obtained by retaining the peptide of the present invention in a liposome containing an acidic phospholipid as a membrane component or a liposome containing a neutral phospholipid and an acidic phospholipid as a membrane component. can get.
- acidic phospholipids as membrane constituents are defined more narrowly than ordinary acidic phospholipids, and more specifically, dilauroylphosphatidylglycerol (DLPG), dimyris Toylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG), gioleylphosphatidylglycerol (D ⁇ PG), yolk phosphatidylglycerol (yolk PGPG) Natural or synthetic phosphatidylglycerols (PG) such as hydrogenated egg yellow phosphatidylglycerol, dilauroyl phosphatidylinositol (DLPI), and dimyristylphosphatidylinositol (DMPI) Dipalmitoylphosphatidylinositol (DPPI ), Distearoyl phosphatidylinosito
- the neutral phospholipids include soybean phosphatidylcholine, egg yolk phosphatidylcholine, hydrogenated soybean phosphatidylcholine, hydrogenated egg yolk phosphatidylcholine, dimyris Tolylphosphatidylcholine (DMPC), dipalmitolylphosphatidylcholine (DPPC), dilauroylphosphatidylcholine (DLPC), distearoylphosphatidylcholine (DSPC), myristoylpalmi Natural or synthetic phosphatidylcholines (PC), such as toylphosphatidylcholine (MPPC), palmitolyl stearylylphosphatidylcholine (PSPC), and dioleylphosphatidylcholine (DOPC), soybean phosphide Fattydylethanolamine, egg yolk phosphatidylethanolamine, hydrogenated soybean phosphatidylethanolamine, hydrogenated egg yolk phosphatidylethanolamine, dimyristylphosphatid
- DPPE dilauroylphosphatidylethanolamine
- DSPE distearoylphosphatidylethanol
- MPPE myristyl palmitolylphosphatidylethanolamine
- PE natural or synthetic phosphatidylethanolamines
- PSPE lusterylphosphatidylethanolamine
- DOPE dioleoylphosphatidylethanolamine
- the liposome membrane is formed according to a conventional method using the acidic phospholipid alone as a component or using the neutral phospholipid and the acidic phospholipid in combination.
- the combined ratio of acidic phospholipids is approximately
- It is preferably about 0.1 to 100% by mole, more preferably about 1 to 90% by mole, and even more preferably about 10 to 50% by mole.
- cholesterol can be further added.
- the fluidity of phospholipids can be adjusted, making it easier to prepare liposomes.
- the cholesterol is usually added and blended in an amount equivalent to the phospholipid, preferably in an amount of 0.5 to 1 equivalent.
- the mixing ratio of the active ingredient and the acidic phospholipid in the liposome dispersion is about 0.5 to 100 equivalents of the active ingredient, preferably about 1 to 60 equivalents to the active ingredient. It is preferably about equivalent, more preferably about 1.5 to 20 equivalent.
- the mol% of the peptide used in the peptide modification of the present invention in the total lipid is from several mol% to about several tens mol%, preferably from about 5 mol% to about 10 mol%, and Usually 5 m %.
- the peptide of the present invention when it itself has an anticancer activity, it may be about 5 to 40 mol%.
- a water-soluble anticancer agent or a substance having an anticancer activity since it is encapsulated in the aqueous layer in the ribosome, it is encapsulated with an efficiency of 10% to 90%.
- the encapsulation efficiency can be as high as 100% when the desired active ingredient is encapsulated in the ribosome membrane.
- a method for producing the ribosome In producing the liposome, various known methods can be used. For example, after dissolving the ribosome membrane constituents in an organic solvent such as chloroform, the solvent is distilled off under reduced pressure to form a lipid film, and the aqueous phase in which the drug is dissolved is added thereto, and the lipid Heat the mixture to a temperature higher than the phase transition temperature, and prepare a liposome dispersion by treating with Portex, homogenize, or the like. Also, a liposome dispersion can be prepared by heating a powdery liposome membrane constituent component to a temperature higher than the phase transition temperature and mixing and stirring with a drug aqueous solution. Any drug aqueous solution can be used as long as the drug is dissolved, and the amount of the drug aqueous solution can be arbitrarily increased or decreased.
- the dispersion of the ribosome obtained in this way is necessary. Accordingly, it is also possible to control the particle size distribution using an ultrafiltration membrane method, for example, using a polycarbonate membrane filter. It is also possible to concentrate using a dialysis membrane.
- preservatives such as benzalkonium chloride, benzene zirconium chloride, black mouth hexidine, parabens (methyl paraben, ethyl paraben, etc.), and fungi and bacteria such as thimerosal.
- Effective preservatives are tonicity agents such as D-mannitol, D-sorbitol, D-xylitol, glycerin, glucose, monetose, sucrose, propylene glycol, etc. Electrolytes such as polyhydric alcohols and sodium chloride, and tocopherol, butylhydroxyanisole, butylhydroxytoluene, ethylenediaminetetraacetate (EDTA) as stabilizers , Cysteine, etc., respectively.
- tonicity agents such as D-mannitol, D-sorbitol, D-xylitol, glycerin, glucose, monetose, sucrose, propylene glycol, etc.
- Electrolytes such as polyhydric alcohols and sodium chloride, and tocopherol, butylhydroxyanisole, butylhydroxytoluene, ethylenediaminetetraacetate (EDTA) as stabilizers , Cysteine, etc., respectively.
- the novel blood vessel-specific peptide of the present invention utilizes the effect of the cancer to return to the neovascular blood of the cancer, and binds a radioactive compound, a fluorescent substance, an enzyme, a biotin, a contrast agent, etc. It can be used as a diagnostic agent for cancer, etc. by performing active targeting for cancer.
- novel blood vessel-specific peptide of the present invention may further include a fatty acid (eg, behenic acid, stearic acid, palmitic acid, myristic acid, or oleic acid), an alkyl group, a cholesteryl group and the like.
- a fatty acid eg, behenic acid, stearic acid, palmitic acid, myristic acid, or oleic acid
- an alkyl group eg., behenic acid, stearic acid, palmitic acid, myristic acid, or oleic acid
- Circulating Liposomes old drugs, New therapeutics., MC Wood 1 e, G. Storm, Eds: Springer-Ver 1 ag Berl in (1998)).
- the details of the production of a pharmaceutical composition containing the above lipid emulsion together with an anticancer agent and a cytokine having anticancer activity are described in detail in the literature of Nampa et al. (Liposomal applications to cancer therapy, Y.Namba, N. Oku, J. Bioact. Compat. Polymers, 8, 158-177 (1993)).
- novel blood vessel-specific peptide of the present invention can be combined with various fatty acids, alkyl groups, cholesteryl groups, and the like to form liposomes and lipid emulsions containing these, for cancer imaging.
- a radioactive compound, a contrast agent, and the like are further bound to the compound, and active targeting of the cancer is performed.
- the compound can be used as a diagnostic agent for cancer. These can thus be used as cancer diagnostics to identify the presence of cancer.
- the use of such diagnostic agents has the advantage of identifying primary tumors as well as metastatic foci, which may not otherwise be detectable. Therefore, the present invention also provides a method for diagnosing cancer, particularly a method for identifying primary cancer and metastatic lesions.
- the neovascular specific peptide is an anti-cancer agent, e.g., a cancer chemotherapy, for returning the agent to the cancer.
- an anti-cancer agent e.g., a cancer chemotherapy
- the present invention also provides a method for treating cancer and cancer metastasis and a method for inhibiting metastasis.
- the neovascular inhibitor or the therapeutic composition for cancer of the present invention comprises a pharmaceutically acceptable carrier together with a neovascular-specific peptide as an active ingredient or a complex of the peptide with another anticancer agent or the like. Is administered to a patient as a pharmaceutical composition containing
- the pharmaceutically acceptable carrier used is well known in the art and can be appropriately selected depending on the form of the pharmaceutical composition to be prepared.
- the carrier may be, for example, an injectable organic ester such as glycol, glycerol, or olive oil.
- a compound that acts to stabilize or increase the absorption of the complex can be used as the carrier, for example.
- Such compounds include, for example, carbohydrates such as glucose, sucrose or dextran, antioxidants such as ascorbic acid or glucanthione, chelating agents, low molecular weight proteins or albumin. Examples of stabilizers and excipients, such as butane, can be exemplified.
- the amount of the active ingredient contained in the neovascular inhibitor or cancer therapeutic composition (formulation) of the present invention can be selected from a wide range. It is not particularly limited. Usually, when the novel blood vessel-specific peptide of the present invention is used alone as an active ingredient, it is contained in the preparation in an amount of about 0.0001 to 70% by weight, preferably about 0.0000. It is desirable to select from the range of the amount contained up to 5% by weight.
- the dosage of the above preparation is not particularly limited, either, and it can be appropriately selected from a wide range according to the desired therapeutic effect, administration method (administration route), treatment period, patient age, gender, and other conditions. it can.
- the dose may range from about 0.01 g / L to about 1 mg of LO / mg, preferably about 0.1 g / L / mg to about 1 mg / L / kg of patient. It is better to be chosen.
- the preparation can be administered not only once per day but also in several divided doses.
- the dose of the neovascular inhibitor or the therapeutic composition for cancer of the present invention prepared by using the neovascular specific peptide of the present invention together with an anticancer agent and a cancer metastasis inhibitor is determined by binding to the neovascular specific peptide of the present invention. For example, it can be appropriately determined depending on the amount of a cancer chemotherapeutic agent (drug) used to have a desired anticancer effect.
- the 5—FU usually contains about 0.1 mg Zkg per day.
- the dose is about 50 mgkg.
- Books used in conjunction with this The amount of the novel blood vessel-specific peptide of the present invention is self-evident, and those skilled in the art can easily understand that such an amount can be regarded as an effective amount of the peptide of the present invention.
- the pharmaceutical composition of the present invention has a characteristic of having an effect of specifically returning to neovascularization of cancer, the administration amount of the cancer chemotherapeutic agent is smaller than the clinical dose used conventionally. It is expected that even a small amount will be effective.
- the neovascular-specific polypeptides of the present invention are combined with a radioactive compound, a contrast agent, and the like for cancer imaging, and are used as active agents against cancer as a diagnostic agent. Getting can be carried out.
- the neovascular-specific polypeptide of the present invention can be used for detecting the presence of neovascularization in cells, tissues, organs, and portions thereof isolated from the human body. According to such use, since the neovascularization is formed by cancer, as a result, the presence of cancer in a sample isolated from the human body can be detected.
- the human sample can be, for example, a tissue section or specimen obtained by biopsy, cells present or adapted in tissue culture. Further, the human sample may be one that has been treated with homogenization, and is preferred.
- FIG. 1 is a bar graph showing the results of a competitive inhibition experiment of each phage and an 8-residue synthesized peptide according to Example 3 (3).
- FIG. 2 is a bar graph showing the results of a competitive inhibition experiment of each phage and a 5-residue synthesized peptide according to Example 3 (3).
- FIG. 3 is a graph showing the angiogenesis inhibitory effect of the dendrimer peptide shown in Example 4 (2).
- FIG. 4 is a graph showing the biodistribution of the liposome solution of the tumor-bearing mouse shown in Example 5 (2).
- FIG. 5 is a graph showing the tumor growth inhibitory effect of the dendrimer peptide shown in (1) of Example 6.
- FIG. 6 is a graph showing the tumor growth inhibitory effect of the peptide of the present invention shown in (6) of Example 6.
- FIG. 7 is a graph showing the tumor growth inhibitory effect of the peptide of the present invention shown in (3) of Example 6.
- FIG. 8 is a graph showing the tumor growth inhibitory effect of the peptide of the present invention shown in (4) of Example 6.
- FIG. 9 is a graph showing the tumor growth inhibitory effect of the peptide of the present invention shown in (5) of Example 6.
- FIGS. 10 and 11 are graphs showing the tumor growth inhibitory effect of the peptide of the present invention shown in (6) of Example 6.
- FIG. 12 is a graph showing the tumor growth inhibitory effect of the peptide-modified liposome of the present invention shown in (1) of Example 7.
- FIG. 13 is a graph showing the affinity of the peptide-modified liposome of the present invention shown in (2) of Example 7 for tumor tissue.
- FIG. 14 is a graph showing the blood stability of the peptide-modified liposome of the present invention shown in (3) of Example 7.
- FIG. 15 is a graph showing the antitumor effect of a ribosome containing the novel blood vessel-specific peptide of the present invention and an anticancer agent as active ingredients according to Example 8.
- 15 residues are included in the phage coat protein pill gene.
- a random amino acid sequence peptide encoding a random amino acid sequence peptide can be introduced to express a random amino acid sequence peptide of 15 residues on the outer surface of the phage.
- the desired fuzzy display library was built.
- Tumor neovessels targeted by neovascular-specific peptide-expressing phages can be induced in vivo by the chambering method (Folkman, J., et al., J. Exp. Med., 133, 275-288 (1971)).
- the chamber ring method is one of the established methods for inducing tumor neovascularization in vivo, in which cancer cells are encapsulated in a ring and implanted subcutaneously in animals. In doing so, it induces new blood vessels in the skin. Since the ring filter has the property of not allowing cells to permeate but permeating only humoral factors, this method does not allow cancer to spread to animal tissues, It can induce neovascularization without damaging cancer cells by immune cells.
- a ring 14 mm outer diameter, 10 mm inner diameter, 2 mm height, 0.2 ml Millipore for carp raising? 10001401, manufactured by Millipore
- B16 BL6 melanoma cells Dr. GL Nicolson dstute for Molecular Medicine Irvine, CA), Cancer Res., 51, 3612-3619 (1997); FEBS Lett., 427, 286-290 (1998), etc.
- (1 x 10 7 cells / 0.18 m 1 in a volume of 0.18 m 1 per chamber ring.
- the entrance The syringe was injected with a syringe and the inlet was closed with a nylon rod (Millipore). Then, the above ring was
- Implantation was performed on the back of C57BL / 6 male mice, and new blood vessels were formed on the back skin of the mice.
- mice tea Nba one-ring Five days after implantation were anesthetized with Nembutal (0. 2 ml i.p.), the (1) obtained in la Ndamupepuchi Dodi spray off ⁇ one di (1 X 1 0 1 1 co Roni 0.2 ml) was administered into the tail vein in 0.2 ml. Four minutes after the administration, the mice were frozen in liquid nitrogen. After thawing the mouse frozen with a dryer, the skin on which the new blood vessels were formed was cut off and its weight was measured.
- the obtained skin was minced, and Dulbecco's modified Eagle culture solution (A) (Nissui Pharmaceutical Co., Ltd.) containing 1 mM phenylmethylsulfonylfluoride (manufactured by Sigma) as a protease inhibitor was used. Catalog No .: Code 05915), 1 ml, and homogenized on ice. Then, the mixture was transferred into an eppendorf tube and mixed with the above-mentioned (A) culture medium (BSA 0.1 lg + 100 mM PI, 100 1 + DMEM 10 ml) containing 1% serum albumin (manufactured by Intergene) in ice-cold form. Washed three times.
- A Dulbecco's modified Eagle culture solution
- A Dulbecco's modified Eagle culture solution
- BSA 0.1 lg + 100 mM PI, 100 1 + DMEM 10 ml
- serum albumin manufactured by Intergene
- NZY medium containing 0.2 xg Zml tetracycline (Sigma) (10 g NZ amine A: Wako Pure Chemical Industries: Code; 541-00241), After dissolving 5g beer yeast extract (trade name: Ebisos, manufactured by Asahi Breweries) and 5g NaCl in 1L of purified water, adding 1ml of 5N NaOH to adjust to pH 7.5, sterilizing by autoclaving, (Stored at room temperature) was added, and the mixture was incubated at 37 ° C for 180 minutes at 180 to 200 rpm.
- Sigma NZY medium containing 0.2 xg Zml tetracycline
- Table 1 shows the recovery rates of the phages obtained by the first to fifth biobanning. As shown in the table, the ratio of the number of phages accumulated at the neovascular site to the number of phages administered via the tail vein, expressed as a percentage, is a percentage of the phage recovery. From this, it was confirmed that phage expressing a peptide that specifically binds to neovascular endothelial cells was recovered.
- the colonies on the plate obtained in the titer measurement after the fourth biobanning were picked at random by 50 colonies each, and re-inoculated into a new NZY plate.
- the cells were cultured at 7 ° C and stored at 4 as a master plate.
- the master plate colonies were each suspended in 50 ml centrifuge tubes containing 20 ml of NZY medium (containing 20 g / ml tetracycline), and then the suspension was incubated at 37-200. Shaking culture was performed at 0 rpm.
- the mixture was centrifuged at 1500 rpm / min for 10 minutes to reprecipitate the phage. Then, the supernatant was removed, and the precipitated phage was resuspended in 200 1 TBS. After centrifugation at 150,000 rpm for 10 minutes to precipitate insoluble substances, the precipitate was transferred to a 0.5 ml eppendorf tube, and phage clone was added at 4 to Saved in.
- Extraction of DNA from the phage clone obtained above was carried out in 1.5 ml eppendorf tubes with phage clone 100/1 and TBS lOOzl and TE saturation.
- the weight of phenol (produced by Nippon Co., Ltd.) was increased to 200, and the mixture was vigorously stirred for 10 minutes, and then centrifuged at 1500 rpm / min for 10 minutes. Then, to the supernatant (aqueous phase) 201, add ⁇ -saturated phenol 2001 and black hole form 201, and vigorously vibrate for 10 minutes as described above. After stirring, the mixture was centrifuged at 1500 rpm / min for 10 minutes.
- the supernatant (aqueous phase) 150 1 ⁇ 250 ⁇ 3 ⁇ sodium acetate 40 40 2 20 mg / m 1 glycogen (Berlinger Minheim ) And ethanol (1 ml), leave in a 1.5 ml Etpendorf tube at 120 for 1 hour, and then rotate 150 000 times. Centrifuged at / min for 10 minutes. Remove the supernatant and remove 1 ml
- Centrifugation was performed at 1500 rpm / min for 10 minutes to remove residual salts. After removing the supernatant, evaporate the water in the tube, and dissolve the precipitated DNA in 10 ml of sterile distilled water.
- DNA was used for peptide sequencing.
- the sequence of the peptide encoded by the phage DNA was determined by the dideoxy method (Proc. Natl. Acad. ScI., USA., 74, 5463-5467 (1977)). This was performed using the THERMO sequence kit (Amersham Life Sciene, Code; US79765, Lot number; 201503) according to the instruction manual for the instrument. The DNA extension reaction was carried out at 96 ° C, 30 seconds, 45 :, 15 seconds, 60, and 30 cycles were performed with 4 minutes as one cycle. This was performed using a DNA sequencer (ABI PRISMTM377 DNA sequencer).
- the obtained tumor was minified, and the phage was infected with Escherichia coli in the same manner as in the above (3), and then cultured. Thereafter, the colony forming units of the phage accumulated in the cancer tissue were measured in the same manner.
- Table 3 shows the affinity of the neovascular-specific peptide display phage for cancer tissue, and the binding ratio of each peptide-expressed phage when the recovery rate of the phage before selection was set to 1. Also described. Table 3
- Meth A sarcoma cells (1 ⁇ 10 6 ) were transplanted into the left abdomen of 5-week-old BALBZc male mice to produce tumor-bearing mice.
- the test be performed by the same method as in (5) above? I'm done.
- the Fmoc-amino acid corresponding to each amino acid from the C-terminal to the second and subsequent amino acids was subjected to an extension reaction at 0.25 mmol according to the synthesis program.
- each peptide of the C-terminal amide is subjected to a condensation reaction of Fmoc-NH-SAL resin with 0.25 mmol of Fmoc-amino acid corresponding to the C-terminal amino acid according to a synthesis program, and thereafter, Fmoc-amino acids corresponding to the second and subsequent amino acids from the C-terminal were sequentially subjected to a condensation reaction to extend the chain.
- each of the thus obtained peptide resins is collected in a polypropylene column (manufactured by Assist), washed with methanol, dried in a vacuum, and subjected to the following operations. Then, the peptide was cut out from the resin to perform a side chain deprotection reaction. That is, each Resin re Agent down preparative K (Reagent K, 82.5% TFA , 5% off et Bruno Ichiru, 5% H 2 0, 5 % thiophosphite two sole (Thi oani so 1 e), 2.5% eth Njichioru) to 2 ml In addition, the reaction was carried out for 60 minutes in a minicolumn.
- Resin re Agent down preparative K Reagent K, 82.5% TFA , 5% off et Bruno Ichiru, 5% H 2 0, 5 % thiophosphite two sole (Thi oani so 1 e), 2.5% eth Njich
- reaction solution was dropped into 8 ml of cold getyl ether to stop the reaction, and at the same time, the peptide was precipitated.
- wash the column with 2 ml of TFA add 5 ml of cold getyl ether, centrifuge, wash the precipitate four times with 10 ml of getyl ether, and wash about 5 ml of 50%
- the peptide was solubilized with cetonitrile and lyophilized. Further, the solubilization and freeze-drying operations were repeated twice to obtain a desired crude freeze-dried product.
- the resin and the amino acid derivative used in the above are all manufactured by Watanabe Chemical Industry Co., Ltd.
- Each peptide isolated in this manner was identified by amino acid sequence analysis and molecular weight measurement by mass spectrometry.
- Each peptide of the amino acid sequence shown in 16 was synthesized according to the peptide solid-phase synthesis method shown in Example 2.
- the peptide of the C-terminal amide structure thus obtained was used as the peptide of the present invention unless otherwise specified.
- the number of phages accumulated in new blood vessels in cancer tissue due to colony formation was calculated, and the tumor accumulation rate of peptide-expressed phages to which synthetic peptides were not administered at the same time was used as a reference value. Then, inhibition of phage accumulation by each synthetic peptide was evaluated.
- the vertical axis indicates fuzz accumulation%
- the horizontal axis indicates fuzz number.
- the open bars indicate the group to which only the phage to which no synthetic peptide was administered (control group)
- the hatched bars indicate the short-chain synthetic peptide shown in SEQ ID NO: 13.
- the black group represents the group to which the short-chain synthetic peptide shown in SEQ ID NO: 14 was administered.
- an eight-residue short-chain synthetic peptide containing WRP which is a common sequence of the synthetic peptides of the amino acid sequences shown in SEQ ID NOs: 5 and 6 (SEQ ID NOs: 13 and 14) ) Suppressed tumor accumulation of the corresponding 15-residue peptide-expressing phage.
- the inhibitory activity was higher than that using the 15-residue synthetic peptide. Further, both showed cross-reactivity, suggesting the importance of the consensus sequence WRP, and further shortening the chain may be possible.
- open bars represent the group administered only the phage to which no synthetic peptide was administered (control group), and black bars represent the group administered the short-chain synthetic peptide shown in SEQ ID NO: 15. (In the case of using No. 5), and the hatched bar indicates the short-chain synthetic peptide administration group shown in SEQ ID NO: 16 (in the case of using No. 6).
- Meth A sarcoma cells (5 x 10 6 cells Zml) were transformed into 5-week-old male 0.2 ml of BALBZc mouse (manufactured by Japan SLC) was subcutaneously administered to the left flank to produce a solid tumor-bearing mouse.
- Six to ten days after transplantation of the sarcoma the day when the diameter of the cancer reaches 4 mm after transplantation into the tumor-bearing mouse is defined as the first day.
- the control is performed using distilled water ( DW) and each of the above dendrimer peptides (1) to (3) were subcutaneously administered at a dose of 20 mg / kg / day (four mice in each group).
- the anti-tumor effect of each dendrimer peptide was determined from 6 days after transplantation by examining changes in body weight and survival as indicators of tumor growth and side effects as well as the short and long diameters of the cancer, as shown below.
- the cancer volume was calculated according to the formula.
- Cancer volume 0.4 X a X b 2 (a: major axis b: minor axis)
- the ordinate indicates the cancer volume (cm 3 )
- the abscissa indicates the number of days (days)
- (1) indicates the dendrimer-peptide administration group of (1)
- (2) indicates the number of days.
- (2) shows the dendrimer peptide administration group
- (3) shows the dendrimer peptide administration group
- (4) shows the distilled water administration group.
- the angiogenesis-specific peptide of the present invention is desirable if its biodistribution is specific to neovascularization of tumors and / or sites around tumors.
- the anti-cancer agent of the present invention can be used as a pharmaceutical composition containing a site kinase having an anti-cancer activity or the like, and can be a DDS drug which can be actively activated against cancer.
- the ribosome prepared by ribosome formation by binding stearic acid to the N-terminal of a 5-residue peptide containing the WRP sequence and the PRP sequence is targeted. Whether or not to accumulate in the tumor was examined.
- the novel blood vessel-specific peptide of the present invention (partial peptide, SEQ ID NO: 15: partial peptide of SEQ ID NO: 5, SEQ ID NO: 16: partial peptide of SEQ ID NO: 6 and SEQ ID NO: 17: partial peptide of SEQ ID NO: 1
- a stearic acid derivative (with Ala added to the N-terminus) was synthesized by the method of Example 2.
- lipid DSPC disearoyl phosphatidylcholine: manufactured by Nippon Seika Co., Ltd.
- cholesterol manufactured by Sigma
- partial peptide stealine three types of neovascular-specific peptides of the present invention
- [Ore bets - 1 - 14 C] labeled co-less tape roll O rate (5 5 5 KB q: Amersham) was added to a molar ratio of 1 0: 5: a click throat Holm solution in a proportion of the 4 It was prepared. Next, the prepared solution was placed in an eggplant-shaped flask, and the mouth form was removed under reduced pressure using a low-pressure evaporator to prepare a lipid thin film. Further, the crotch film was completely removed under reduced pressure and dried. After vacuum drying for 60 minutes, it was hydrated with 0.3 M glucose (DSPC concentration: 5.0 mM).
- an anticancer substance such as 5 FU and doxorubicin, which are isotonic with glycerin, etc., as active ingredients, and an antitumor active ingredient were added as active ingredients.
- an anticancer substance such as 5 FU and doxorubicin, which are isotonic with glycerin, etc.
- an antitumor active ingredient were added as active ingredients.
- PBS Dulbecco's phosphate buffered saline
- PBS Dulbecco's phosphate buffered saline
- an anticancer agent such as adriamycin by a remote-loading method after addition or by preparing a liposome. Since the peptide itself has an antitumor effect as shown in Example 3, the following preparation steps did not include the anticancer substance and the antitumor active ingredient as follows: .
- the above solution was repeatedly frozen and thawed by heating at 70 ° C three times, and then the solution was warmed for 10 minutes using a warm-bath sonicator (trade name: ULTRASONIK250: manufactured by Rabosco Corporation). During the sonication, stirring was performed. Next, the membrane was passed through an polycarbonate (manufactured by Leipex) three times through a polycarbonate membrane having a pore size of 100 nm (nuclear pore carbonate: manufactured by Costar). A ribosome (dispersion solution) containing a molecule in which stearic acid is bound to the N-terminus of a new blood vessel-specific peptide (partial peptide) of the present invention was obtained. In this case, the partial peptide is designed to decorate the surface of the ribosome.
- DSPC DSPC
- cholesterol in 7.5 ml of 7.5 / mol 3.75 / mol and 3 ⁇ mol, respectively.
- a liposomal dispersion was obtained.
- Meth A sarcoma cells (0.26 ml ⁇ 1 ⁇ 10 6 ) were implanted subcutaneously on the ventral side of 5-week-old BALBZ c mice to form solid tumors. 10 days later, the three liposome dispersions prepared in (1) above were administered to the tumor-bearing mice under anesthesia. The distribution in the body was examined. As a control, a ribosome dispersion containing no synthetic peptide was administered. The tumor-bearing mice tested were 2-3 in each group.
- the tumor-bearing mice were bled and then sacrificed by cervical dislocation, dissected, and blood, cancer tissue, heart, lung, liver, spleen, and kidney were collected. Each organ weight was measured.
- the blood was transferred to an Eppendorf tube, centrifuged at 300 rpm for 5 minutes, and the obtained serum 501 was stored in a vial.
- Each organ was cut to about 100 mg, put in a vial in the same way, and the organ was weighed and stored (each organ was obtained from two places).
- each organ in the vial is minced and 1 ml After adding a tissue lysate (Solno Blue: manufactured by NEN Research Productions), the mixture was left overnight in a 50 incubator (Personal DX: manufactured by Thaitech Co., Ltd.). The next day, 0.5 ml of isopropanol (manufactured by Wako Pure Chemical Industries, Ltd.) was added as a defoaming agent, and 0.5 ml of hydrogen peroxide was added as a decolorizing agent, and the mixture was left for several hours. .
- tissue lysate Solno Blue: manufactured by NEN Research Productions
- Figure 4 shows the results.
- the numerical values indicate the recovered amount (% dose) of the administered peptide-modified liposome in 100 mg of the tumor tissue.
- the neovascular specific peptide of the present invention (partial peptide, SEQ ID NO: 15: partial peptide of SEQ ID NO: 5; RWRPA, SEQ ID NO: 16: partial peptide of SEQ ID NO: 6) C; HWRPW and SEQ ID NO: 17: SEQ ID NO: 1
- APRPG Amin-peptide
- liposomes modified with these angiogenesis-specific peptides of the present invention have a higher blood retention property than ribosomes not modified with such peptides (without addition of control or peptide). Also showed a tendency to increase.
- the dendrimer of the peptide of SEQ ID NO: 1 synthesized in (1) of Example 4 was 10 mg / kg X 2 / day and 20 mg / kg X 2 days of the peptide.
- Each of 66 distilled water (DW) was administered subcutaneously from 1 to 10 days after tumor cell transplantation according to the method of (2) in Example 4 to examine the tumor growth inhibitory effect. .
- the number of mice used in the experiment was 4 to 6 per group.
- the obtained results are shown in FIG. 5 (vertical axis: tumor volume (cm 3 ), horizontal axis: days after transplantation of tumor cells (days)) in the same manner as in FIG.
- the open circles represent the dendrimer peptide of 10 mg kg X 2 days
- the black circles represent the dendrimer peptide of 20 mg Z kg X 2 Z days
- the open squares represent the
- the dendrimer of the peptide whose sequence was arbitrarily changed was 20 mg Z kg XS / day and the black squares indicate the groups to which distilled water was administered, respectively.
- Physiological saline was subcutaneously administered to each of the three synthesized short-chain peptides and control until day 11 after tumor cell transplantation according to the method of Example 4, (2).
- the effect of suppressing tumor growth was examined.
- the obtained results are shown in Fig. 6, as in Fig. 3.
- the open circles represent the saline administration group
- the black circles represent the peptide administration group of SEQ ID NO: 19
- the white squares represent the peptide administration group of column E 17
- the black squares represent the peptide administration group.
- the peptide administration group of SEQ ID NO: 20 is shown.
- tumor growth was observed in the PRP-containing peptide-administered group (SEQ ID NO: 19 and the peptide-administered group) in the first half of the sequence of SEQ ID NO: 1. The suppression tendency was confirmed.
- Each of the peptides synthesized above was treated with 2 O mg kg of Z day or distilled water (DW) as a control in accordance with the method of Example 4 (2) after tumor cell transplantation.
- DW distilled water
- the number of mice used in the experiment was 3 to 5 in each group. The results are shown in Fig. 7, as in Fig. 3.
- the open circles represent the groups administered with distilled water
- the black circles represent the groups administered with the peptide of SEQ ID NO: 5
- the open squares represent the groups administered with the peptide of SEQ ID NO: 22 (comparison group; The group administered with the peptide of 15 residues)
- the black squares indicate the group to which the peptide of SEQ ID NO: 13 was administered
- the open triangles indicate the group to which the peptide of SEQ ID NO: 21 was administered.
- saline was administered at 20 mg / kg day or as a control for each of the peptides synthesized above.
- the tumor growth inhibitory effect was examined by subcutaneous administration. The number of mice used in the experiment was 4 to 5 per group.
- Fig. 8 shows the results in the same way as Fig. 3.
- open circles indicate the peptide-administered group of SEQ ID NO: 23
- black circles indicate the peptide-administered group of SEQ ID NO: 24
- open squares indicate the peptide-administered group of SEQ ID NO: 25 and the black square. Indicates a physiological saline administration group, respectively.
- Example 1 in order to examine a peptide sequence which has an effect on the tumor growth inhibitory effect of a short-chain peptide related to the peptide of SEQ ID NO: 6, the following SEQ ID NO: In Example 1, the peptide of No. 6 and its three partial sequences (SEQ ID NOs: 26, 14 and 16) and the comparative peptide (SEQ ID NO: 27) obtained by arbitrarily replacing the sequence of SEQ ID NO: 6 were prepared. It was synthesized by a peptide solid-phase synthesis method according to method 2 and used for this test. 9
- Fig. 9 shows the results in the same way as Fig. 3.
- the open circles represent distilled water administration group
- the black circles represent peptide administration group of SEQ ID NO: 6
- the white squares represent peptide administration group of SEQ ID NO: 26
- the black squares represent SEQ ID NO: 14.
- the open triangles indicate the peptide-administered group of SEQ ID NO: 16 and the black triangles indicate the peptide-administered group of SEQ ID NO: 27, respectively.
- Table 10 shows that SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 5 and 6 A peptide containing a WRP sequence of 3 to 4 residues derived from both sequences and a 5-residue peptide in which each amino acid residue in the WRP sequence was substituted with alanine (A: Ala), respectively.
- the peptide was synthesized by solid-phase synthesis according to the method of Example 2 and used in this test.
- SEQ ID NO: 28 4-position 4-residue peptide at position 2—5 of SEQ ID NO: 5 SEQ ID NO: 9 9-1-1 2-position 4-residue peptide at SEQ ID NO: 3 SEQ ID NO: 3 1 10—1 3 position 4 residue peptide of SEQ ID NO: 6 SEQ ID NO: 3 3-residue peptide common to SEQ ID NOS: 5 and 6 SEQ ID NO: 3
- tumor cells were transplanted with each of the peptides synthesized above at a dose of 20 mg / kg Z-day or distilled water or saline as a control.
- mice used in the experiment were 5 to 6 in each group.
- the results are shown in FIG. 10 (results of the peptides of SEQ ID NOs: 28 to 32) and FIG. 11 (results of the peptides of SEQ ID NOs: 33 to 35) in the same manner as in FIG.
- open diamonds indicate the peptide-administered group of SEQ ID NO: 32
- black circles indicate the group administered with distilled water
- open squares indicate the peptide-administered group of SEQ ID NO: 28
- black squares indicate the SEQ ID NO: 29.
- the open triangles indicate the peptide administration group of SEQ ID NO: 30 and the black triangles indicate the peptide administration group of SEQ ID NO: 31, respectively.
- the open circles indicate the physiological saline administration group
- the black circles indicate the peptide administration group of SEQ ID NO: 33
- the white squares indicate the peptide administration group of SEQ ID NO: 34
- the black square indicates the array. number Each of the 35 peptide administration groups is shown.
- the WRP sequence is important for having antitumor activity, and a short-chain peptide comprising at least 4 to 5 residues or more containing the WRP sequence is expected to have antitumor activity. It was confirmed that it had.
- Peptide-modified ribosomes having the sequences of SEQ ID NOS: 15, 16 and 17 were prepared in accordance with (1) of Example 5, and their tumor growth inhibitory effects were examined. However, the preparation of the peptide modified ribosome, the addition of [O, single-preparative-1 one 14 (] target ⁇ Ko less Te rolls O rate Bok was performed.
- Each of the peptide-modified liposome dispersions prepared above 2 O mg / kg Z-day or saline as control and control ribosome (without peptide) was administered subcutaneously three times on days 4, 6, and 8 after tumor cell transplantation according to the method of (2) in Example 4, and the tumor growth inhibitory effect of each peptide-modified ribosome was examined. I was. Five mice were used in each group for the experiment. The results are shown in Fig. 12 as in Fig. 3.
- the open diamonds represent the control group
- the open squares represent the saline administration group
- the open circles represent the peptide-modified ribosomes of SEQ ID NO: 17
- Open triangles indicate the peptide-modified ribosome administration group of SEQ ID NO: 15
- black squares indicate the peptide-modified ribosome administration group of SEQ ID NO: 16.
- the high antitumor effect was determined by the peptide-modified ribosome of SEQ ID NO: 15> the peptide-modified liposome of SEQ ID NO: 16> the peptide-modified ribosome of SEQ ID NO: 17 It turned out that the order was as follows. Also, from FIG. 12, it was confirmed that the short-chain peptide having the WRP sequence had stronger antitumor activity.
- the results of the biodistribution test of the peptide-modified liposome of Example 5 indicate that the liposome modified with the peptide having the sequence of SEQ ID NO: 17 was the most tumor-specific. By changing the molar ratio in the liposome, the change in specificity for the tumor was examined.
- a liposome dispersion was prepared according to (1) of Example 5. did. At that time, umami DSPC (distearoylphosphatidylcoline: manufactured by Nippon Seika Co., Ltd.), cholesterol (manufactured by Sigma) and the new blood vessel specific peptide of the present invention (SEQ ID NO: 17: partial peptide of SEQ ID NO: 1)
- the molar ratio of the stearic acid derivative (with A1a added to the N-terminus of the compound) is 10: 5: 2 (referred to as PRP—20), 10: 5: 1 (PRP—10) ), 10: 5: 0.5 (referred to as PRP-5), and 10: 5: 0 (referred to as content control and control), respectively.
- PRP—20 The molar ratio of the stearic acid derivative (with A1a added to the N-terminus of the compound) is 10: 5: 2 (referred to as PRP—20), 10: 5: 1 (PRP—10) ), 10: 5:
- Fig. 14 The results of the serum stability (aggregation degree) obtained are shown in Fig. 14 (vertical axis: aggregation degree, horizontal axis: each test liposome).
- the stability of the liposome preparation of the present invention in serum is at least 10 mol in the amount of the neovascular-specific peptide which is one of the active ingredients of the ribosome preparation of the present invention. It was confirmed that there was no effect on agglomeration at% or less.
- Example 8 Examination of Antitumor Effect of Libosome Preparation Containing Neovascular Specific Peptide and Anticancer Agent as Effective Components
- Example 7 (2) Based on the results of the effect of the peptide-modified liposomes of the present invention obtained in Example 7 (2) on the affinity to tumor tissue, 5 mol% of the peptide of SEQ ID NO: 17 was synthesized. The antitumor effect of the following liposome in which adriamycin, which is known as an anticancer agent, was encapsulated in a peptide-modified liposome containing the same was examined.
- stearic acid of the neovascular-specific peptide of the present invention (partial peptide, SEQ ID NO: 17: partial peptide of SEQ ID NO: 1 with A1a added to the ⁇ end)
- the derivative was synthesized by the method of Example 2.
- lipid DSPC disearyl phosphatidyl cocoline: manufactured by Nippon Seika Co., Ltd.
- cholesterol manufactured by Shidama
- neovascular-specific peptide of the present invention a stearic acid derivative of a partial peptide
- a molar ratio of 10: 5: 0.5 was prepared. That is, 400 mM / zl of 100 mM DSPC, 200 a1 of 100 mM cholesterol and 100 mM of cholesterol. 1 to 20 m ⁇ of the peptide of the present invention was added to prepare a clog form solution containing a molar ratio of 10: 5: 0.5.
- the prepared solution was placed in an eggplant-shaped flask, and the mouth mouth form was removed under reduced pressure overnight at a vacuum evaporator to prepare a lipid thin film. Further, the clog form was completely removed under reduced pressure and dried. After vacuum drying for 60 minutes, it was hydrated with 1 ml of 0.3 M citric acid solution (pH 4.0) (DSPC concentration; 40 mM).
- the above solution was repeatedly frozen and thawed by heating at 70 ° C three times, and then the solution was warmed for 10 minutes using a warm bath type sonicator (trade name: ULTRASONIK250: manufactured by Rabosco Corporation). The mixture was sonicated and stirred. Then, it was passed three times through an extruder (manufactured by Leipex) through a polycarbonate film (nucleopore membrane, manufactured by Coaster) having a pore size of 100 nm. A liposome (dispersion solution) containing a molecule in which stearic acid is bound to the N-terminal of the new blood vessel-specific peptide (partial peptide) of the present invention is obtained. In this case, the partial peptide is in the form of modifying the surface of the liposome.
- a 0.5 M sodium carbonate solution was added to the liposome dispersion to adjust the pH of the aqueous phase outside the liposome to 7.5.
- dilute with 20 mM HEPES buffer to make a total volume of 2.O ml
- Add 0.58 ml of a 10 mg no-m1 adriamycin (manufactured by Shidama) solution incubate at 60 ° C for 1 hour, and transfer to the aqueous layer of ribosome. Adriamycin was enclosed.
- the prepared solution was centrifuged for 5 minutes (CS120EX, manufactured by Hitachi, Ltd .; 100,000 g) to precipitate ribosomes, and the supernatant containing unadhered adriamycin was removed.
- the precipitate was redispersed in a 111 M 0.3M glucose solution, and the amount of adriamycin encapsulated was calculated by the quantitative method described below.
- the adriamycin was diluted to 1.1 mgm 1 (10 mg / kg) to obtain a neovascular-specific ribosome (dispersion liquid) of the present invention in which adriamycin was encapsulated.
- CS120EX manufactured by Hitachi, Ltd .; 100,000 g
- DSPC, cholesterol and the novel vascular-specific peptide of the present invention were prepared in 40 ml, 5.5 ml and 20 ml, respectively, in 5.5 ml.
- (Dispersion liquid) DSPC concentration: 7.3 m ⁇ ).
- the enclosing rate was 90% or more.
- Meth A sarcoma cells (1 ⁇ 10 6 cells / mouse) were subcutaneously administered to the left flank of 5-week-old male BALB / c mice (manufactured by SLC Japan) to produce solid tumor-bearing mice.
- the day of transplantation was designated as Day 1, and on days 6, 9, and 12, the solvent controls were 0.3 M glucose solution (solvent) and adriamycin (ADR) Troll ribosome (the neonatal blood of the present invention) Liposomes containing an anticancer drug that does not contain tube-specific peptides), free ADR dissolved in 0.3 M glucose so that the ADR of the anticancer drug is 5 mg / kg (mouse)
- Each of the solution and the angiogenesis-specific peptide-modified ribosome of the present invention encapsulating the ADR prepared in the above (1) was administered into the tail vein.
- the number of tumor-bearing mice used for the test was 5 per group.
- the antitumor effect of each administered drug was measured 5 days after tumor implantation by measuring tumor volume as an index of tumor growth, change in mouse body weight as an index of side effects, and the number of days alive. The evaluation was carried out in the same way as in (2).
- the vertical axis indicates the tumor volume
- the horizontal axis indicates the number of days after tumor implantation.
- (1) is a group to which a solvent is administered
- (2) is a group to which ADR-encapsulated control ribosome is administered
- (3) is a group to which a free ADR solution is administered
- (4) is a newborn of the present invention in which ADR is encapsulated.
- the vascular-specific peptide-modified liposome administration group is shown, respectively.
- a novel neovascular-specific peptide is provided.
- a molecular drug as a ligand for neovascular endothelial cells in a cancer tissue is provided. Therefore, it is possible to provide a cancer diagnostic agent, a cancer diagnostic method, a cancer therapeutic method, etc., which can be applied to DDS preparations that can selectively deliver drugs to target tissues and contribute to the improvement of cancer therapeutic effects. It will be possible.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99947941A EP1122262B1 (en) | 1998-10-16 | 1999-10-15 | Neovascular-specific peptides |
US09/807,278 US6753310B1 (en) | 1998-10-16 | 1999-10-15 | Neovascular-specific peptides |
CA002347136A CA2347136A1 (en) | 1998-10-16 | 1999-10-15 | Neovascular-specific peptides |
DK99947941.3T DK1122262T3 (da) | 1998-10-16 | 1999-10-15 | Neovaskulær-specifikke peptider |
DE69941877T DE69941877D1 (de) | 1998-10-16 | 1999-10-15 | Neovaskular-spezifische peptide |
JP2000577201A JP4439120B2 (ja) | 1998-10-16 | 1999-10-15 | 新生血管特異的ペプチド |
AT99947941T ATE453667T1 (de) | 1998-10-16 | 1999-10-15 | Neovaskular-spezifische peptide |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29519898 | 1998-10-16 | ||
JP10/295198 | 1998-10-16 | ||
JP19470699 | 1999-07-08 | ||
JP11/194706 | 1999-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000023476A1 true WO2000023476A1 (fr) | 2000-04-27 |
Family
ID=26508673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/005730 WO2000023476A1 (fr) | 1998-10-16 | 1999-10-15 | Peptides specifiques pour la neovascularisation |
Country Status (11)
Country | Link |
---|---|
US (1) | US6753310B1 (ja) |
EP (2) | EP1783140A3 (ja) |
JP (1) | JP4439120B2 (ja) |
AT (1) | ATE453667T1 (ja) |
CA (2) | CA2622786A1 (ja) |
CY (1) | CY1109881T1 (ja) |
DE (1) | DE69941877D1 (ja) |
DK (1) | DK1122262T3 (ja) |
ES (1) | ES2337321T3 (ja) |
PT (1) | PT1122262E (ja) |
WO (1) | WO2000023476A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003018748A3 (en) * | 2001-08-16 | 2004-05-27 | Kimberly Clark Co | Anti-cancer and wound healing compounds |
US6974791B2 (en) * | 2000-03-16 | 2005-12-13 | The University Of Pittsburgh | Endothelial specific targeting |
JP2006501196A (ja) * | 2002-07-18 | 2006-01-12 | へリックス バイオファーマ コーポレイション | 癌細胞増殖を阻害するためのウレアーゼの使用 |
JP2009078993A (ja) * | 2007-09-25 | 2009-04-16 | Japan Science & Technology Agency | カーボンナノホーン |
JP2011512364A (ja) * | 2008-02-22 | 2011-04-21 | インター−ケイ ピーティーワイ リミテッド | 治療用ペプチド |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7186693B2 (en) * | 2001-08-16 | 2007-03-06 | Kimberly - Clark Worldwide, Inc. | Metalloproteinase inhibitors for wound healing |
US7071164B2 (en) * | 2001-08-16 | 2006-07-04 | Kimberly-Clark Worldwide, Inc. | Anti-cancer and wound healing compounds |
US7148194B2 (en) * | 2002-12-30 | 2006-12-12 | Kimberly-Clark Worldwide, Inc. | Method to increase fibronectin |
US7189700B2 (en) * | 2003-06-20 | 2007-03-13 | Kimberly-Clark Worldwide, Inc. | Anti-chrondrosarcoma compounds |
US8440217B1 (en) | 2005-06-15 | 2013-05-14 | Mawaheb M. EL-Naggar | Method and system with contact lens product for treating and preventing adverse eye conditions |
WO2009048870A1 (en) * | 2007-10-08 | 2009-04-16 | Baylor College Of Medicine | Peptide dendrimers: affinity reagents for binding noroviruses |
EP2504351A4 (en) * | 2009-11-23 | 2013-10-30 | Palatin Technologies Inc | MELANOCORTIN-1 RECEPTOR-SPECIFIC LINEAR PEPTIDE |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998012226A1 (en) * | 1996-09-20 | 1998-03-26 | The Burnham Institute | Methods of ameliorating cancer and of inhibiting angiogenesis by using fibronectin |
WO1998049322A1 (en) * | 1997-04-26 | 1998-11-05 | Peter Sonderegger | Neurotrypsin |
WO1999029858A1 (en) * | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Soluble inhibitors of vascular endothelial growth factor and use thereof |
WO1999054456A1 (en) * | 1998-04-17 | 1999-10-28 | Aventis Pharma Deutschland Gmbh | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN αv-SUBUNIT EXPRESSION |
WO1999055865A1 (en) * | 1998-04-29 | 1999-11-04 | Genesis Research And Development Corporation Limited | Polynucleotides isolated from skin cells and methods for their use |
WO1999061476A1 (en) * | 1998-05-22 | 1999-12-02 | Abbott Laboratories | Peptide antiangiogenic drugs |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622852A (en) * | 1994-10-31 | 1997-04-22 | Washington University | Bcl-x/Bcl-2 associated cell death regulator |
ES2227614T3 (es) * | 1995-11-16 | 2005-04-01 | Novartis Ag | Metodo para seleccionar compuestos que interaccionan con la proteina quinasa rac. |
JPH11243964A (ja) * | 1998-03-03 | 1999-09-14 | Natl Food Res Inst | イネオルニチンカルバミルトランスフェラーゼ遺伝子、該遺伝子を含むベクター及び形質転換体 |
-
1999
- 1999-10-15 US US09/807,278 patent/US6753310B1/en not_active Expired - Fee Related
- 1999-10-15 CA CA002622786A patent/CA2622786A1/en not_active Abandoned
- 1999-10-15 AT AT99947941T patent/ATE453667T1/de active
- 1999-10-15 WO PCT/JP1999/005730 patent/WO2000023476A1/ja active Application Filing
- 1999-10-15 JP JP2000577201A patent/JP4439120B2/ja not_active Expired - Fee Related
- 1999-10-15 EP EP06021030A patent/EP1783140A3/en not_active Withdrawn
- 1999-10-15 DE DE69941877T patent/DE69941877D1/de not_active Expired - Lifetime
- 1999-10-15 EP EP99947941A patent/EP1122262B1/en not_active Expired - Lifetime
- 1999-10-15 PT PT99947941T patent/PT1122262E/pt unknown
- 1999-10-15 CA CA002347136A patent/CA2347136A1/en not_active Abandoned
- 1999-10-15 DK DK99947941.3T patent/DK1122262T3/da active
- 1999-10-15 ES ES99947941T patent/ES2337321T3/es not_active Expired - Lifetime
-
2010
- 2010-02-25 CY CY20101100192T patent/CY1109881T1/el unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998012226A1 (en) * | 1996-09-20 | 1998-03-26 | The Burnham Institute | Methods of ameliorating cancer and of inhibiting angiogenesis by using fibronectin |
WO1998049322A1 (en) * | 1997-04-26 | 1998-11-05 | Peter Sonderegger | Neurotrypsin |
WO1999029858A1 (en) * | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Soluble inhibitors of vascular endothelial growth factor and use thereof |
WO1999054456A1 (en) * | 1998-04-17 | 1999-10-28 | Aventis Pharma Deutschland Gmbh | ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN αv-SUBUNIT EXPRESSION |
WO1999055865A1 (en) * | 1998-04-29 | 1999-11-04 | Genesis Research And Development Corporation Limited | Polynucleotides isolated from skin cells and methods for their use |
WO1999061476A1 (en) * | 1998-05-22 | 1999-12-02 | Abbott Laboratories | Peptide antiangiogenic drugs |
Non-Patent Citations (1)
Title |
---|
SATO T.N. ET AL.: "Tei-1 and tie-2 defube another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system", PROC. NATL. ACAD. SCI. USA,, vol. 90, no. 20, 1993, pages 9355 - 9358, XP002935528 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6974791B2 (en) * | 2000-03-16 | 2005-12-13 | The University Of Pittsburgh | Endothelial specific targeting |
WO2003018748A3 (en) * | 2001-08-16 | 2004-05-27 | Kimberly Clark Co | Anti-cancer and wound healing compounds |
JP2006501196A (ja) * | 2002-07-18 | 2006-01-12 | へリックス バイオファーマ コーポレイション | 癌細胞増殖を阻害するためのウレアーゼの使用 |
JP2011207913A (ja) * | 2002-07-18 | 2011-10-20 | Helix Biopharma Corp | 癌細胞増殖を阻害するためのウレアーゼの使用 |
JP2013213055A (ja) * | 2002-07-18 | 2013-10-17 | Helix Biopharma Corp | 癌細胞増殖を阻害するためのウレアーゼの使用 |
JP2009078993A (ja) * | 2007-09-25 | 2009-04-16 | Japan Science & Technology Agency | カーボンナノホーン |
JP2011512364A (ja) * | 2008-02-22 | 2011-04-21 | インター−ケイ ピーティーワイ リミテッド | 治療用ペプチド |
Also Published As
Publication number | Publication date |
---|---|
EP1122262B1 (en) | 2009-12-30 |
JP4439120B2 (ja) | 2010-03-24 |
PT1122262E (pt) | 2010-01-27 |
DK1122262T3 (da) | 2010-04-19 |
EP1122262A1 (en) | 2001-08-08 |
CY1109881T1 (el) | 2014-09-10 |
CA2347136A1 (en) | 2000-04-27 |
EP1122262A4 (en) | 2003-05-21 |
ATE453667T1 (de) | 2010-01-15 |
US6753310B1 (en) | 2004-06-22 |
ES2337321T3 (es) | 2010-04-22 |
EP1783140A3 (en) | 2007-07-11 |
DE69941877D1 (de) | 2010-02-11 |
EP1783140A2 (en) | 2007-05-09 |
CA2622786A1 (en) | 2000-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008296733B2 (en) | VEGFR-1/NRP-1 targeting peptides | |
JP4528989B2 (ja) | インフルエンザウイルス・ヘマグルチニン結合性ペプチド | |
CN110790829B (zh) | pHLIP胞外段作为抗原制备的抗体在制备抗肿瘤药物中的应用 | |
WO2000023476A1 (fr) | Peptides specifiques pour la neovascularisation | |
WO2017210693A1 (en) | Protein polymer fusions for subcutaneous delivery of small molecules | |
JP2004510811A (ja) | 抗癌剤を封入したリポソーム及び悪性腫瘍の治療におけるその使用方法 | |
US10611796B2 (en) | Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines | |
EP1581790B1 (en) | Peptides that home to tumor lymphatic vasculature and methods of using same | |
EP1616875A1 (en) | GD3-mimetic peptides | |
JP2004331630A (ja) | Peg結合ペプチド | |
ES2365084T3 (es) | Derivados del péptido vapeehptllteaplnpk biológicamente activos. | |
KR101109163B1 (ko) | 타이로신-세린-발린(ysv)을 포함하는 생물학적 활성펩티드 | |
WO2005041882A2 (en) | Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs | |
US20080188421A1 (en) | Hunter-Killer Peptides and Methods of Use | |
US20080146510A1 (en) | Biologically active peptide vapeehptllteaplnpk derivatives | |
JP5924593B2 (ja) | 抗癌剤の活性増強剤 | |
US20230374113A1 (en) | Ferritin nanocage fused with pd-l1-binding peptide 1 and use thereof as anticancer immunotherapy agent | |
CN106589064A (zh) | 高活性的肿瘤抑制剂及其制法和应用 | |
JPH03127742A (ja) | 癌転移抑制剤 | |
JP2003093077A (ja) | erbB−2関連ペプチド | |
JPH1143445A (ja) | 抗腫瘍剤 | |
JP2007161592A (ja) | 癌組織結合性オリゴペプチド | |
JP2002326999A (ja) | Gd3模倣ペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 577201 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09807278 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2347136 Country of ref document: CA Ref country code: CA Ref document number: 2347136 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999947941 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999947941 Country of ref document: EP |